重视代谢相关脂肪性肝病的特征与预后临床研究*

doi:10.3969/j.issn.1672-5069.2021.03.002

Abstract

Wang Mengyu, Yang Ruixu, Fan Jiangao. Clinical feature and outcomes of patients with metabolic associated fatty liver diseases[J]. Journal of Practical Hepatology, 2021, 24(3): 308-311.

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性病专家委员会. NAFLD防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2):177-186.
[2]Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020, 158(7):1999-2014,e21.
[3] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020, 73(1):202-209.
[4] Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int, 2020, 14(6):889-919.
[5] Zheng KI, Fan JG, Shi JP, et al.From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. Chin Med J (Engl), 2020, 133(19):2271-2273.
[6] Lin SZ, Chen YW, Fan JG. NAFLD to MAFLD: Conceptual changes for clinicians, researchers and patients. J Dig Dis, 2020, 21(11):604-609.
[7] 黄磊杰, 许炎煌, 范建高. 重视非酒精性脂肪性肝病异质性的临床研究. 中华肝脏病杂志, 2020, 28(3):193-197.
[8] 范建高, 曾静. 非酒精性脂肪性肝病的流行现状与危害. 中华消化杂志, 2020, 40(9):577-580.
[9] Zou ZY, Fan JG. Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease.J Hepatol, 2020, 73(1):214-216.
[10] Zou ZY,Wong Vincent WS, Fan JG. Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-analytic assessment of prevalence, genetic, metabolic and histological profiles. J Dig Dis, 2020, 21(7):372-384.
[11] Paik JM, Golabi P, Younossi Y, et al. Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of NAFLD. Hepatology, 2020, 72(5):1605-1616.
[12] Zhang J, Lin S, Jiang D, et al.Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors? Liver Int, 2020, 40(3):496-508.
[13] Ren TY, Fan JG.What are the clinical settings and outcomes of lean NAFLD? Nat Rev Gastroenterol Hepatol. 2021[ahead of print].
[14] 李俊缨, 周玲, 陈金军. 非酒精性脂肪性肝病高危人群:监测与防治. 实用肝脏病杂志, 2020, 23(5):612-614.
[15] 张伟, 施军平. 创建MAFLD防治新模式, 合力推进分层全层管理. 实用肝脏病杂志, 2020, 23(5):609-611.

Clinical feature and outcomes of patients with metabolic associated fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Chen, Wang Lianfa, Wang Yan, et al. Serum liver and kidney function tests and myocardial enzymes in 112 patients with coronavirus-19 pneumonia [J]. Journal of Practical Hepatology, 2021, 24(3): 351-354.
[2]	Liu Songtao, Meng Qinghua, Lyu Jun, et al. Clinical feature and prognosis of lymphoma patients with chemotherapy-induced liver failure [J]. Journal of Practical Hepatology, 2021, 24(3): 383-386.
[3]	Kong Xuejie, Li Jiang, Li Haotian, et al. Clinical feature and efficacy of different prognostic scoring models in patients with acute-on-chronic liver failure with different underlying liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 387-390.
[4]	Su Yayong, Xu Chengrun, Guo Yongmu, et al. Risk factors of death in patients with hepatitis B virus-related acute on chronic liver failure [J]. Journal of Practical Hepatology, 2021, 24(3): 391-394.
[5]	Gao Huiru, Gao Huibin, Peng Zhao, et al. Clinical feature and impacting factors of esophageal and gastric variceal bleeding in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(3): 395-398.
[6]	Li Hua, Wen Jianghua, Wu Yingchun, et al. Clinical features of patients with alcoholic cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(3): 411-414.
[7]	Dang Ling, Jia Ai, Wang Fang. Prognosis of patients with subacute liver failure by serumlipopolysaccharide binding protein and sCD163 levels [J]. Journal of Practical Hepatology, 2021, 24(3): 447-448.
[8]	Zhang Weina, Ding Chuangang, Zhao Hongying, et al. Changes of serum IFN-γ and IL-18 levels in children with cytomegalovirus hepatitis [J]. Journal of Practical Hepatology, 2021, 24(2): 208-211.
[9]	Wang Jiangli, Pei Lingyan, He Jingjing, et al. Clinical value of serum PTX3 and sTWEAK in predicting death of patients with decompensated hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(2): 236-239.
[10]	Sun Wenxia, Wu Shuzhi. Clinical features of IgG4-related sclerosing cholangitis:systemic literature review of 100 cases [J]. Journal of Practical Hepatology, 2021, 24(1): 83-86.
[11]	Liu Zhen,Pan Guangdong,Zhou Zheng,et al. Expression of copb2 gene incancerous tissues in patients with hepatocellular carcinoma and its relationship with prognosis [J]. Journal of Practical Hepatology, 2021, 24(1): 115-118.
[12]	Zhang Jianrong, Gu Erli, Wang Zhongcheng, et al. Comparison of clinical characteristics of patients with autoimmune hepatitis, primary biliary cholangitis and AIH/PBC overlap syndrome [J]. Journal of Practical Hepatology, 2020, 23(6): 829-832.
[13]	Guo Wencheng, Li Na, Wang Fang, et al. Short-term efficacy oftranscatheter arterial chemoembolization with ¹³¹I methicone monoclonal antibody in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2020, 23(6): 877-880.
[14]	Liu Songtao, Li Juan, Yu Houwei, et al.. Clinicalfeatures of nine patients with malignant lymphoma and liver injury [J]. Journal of Practical Hepatology, 2020, 23(5): 650-653.
[15]	Xing Xiaoyan,Huang Liangmiao, Fu Aixian,et al.. Short-term observation of yinzhihuang and adenosine methionine in treatment of patients withintrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2020, 23(5): 670-673.